Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;65(1):10.1002/pbc.26710.
doi: 10.1002/pbc.26710. Epub 2017 Jul 11.

Central nervous system relapse of rhabdomyosarcoma

Brian De  1 , Michael D Kinnaman  2 , Leonard H Wexler  2 , Kim Kramer  2 , Suzanne L Wolden  1
Affiliations

Central nervous system relapse of rhabdomyosarcoma

Brian De et al. Pediatr Blood Cancer. 2018 Jan.

Erratum in

Abstract

Purpose: The optimal management of central nervous system (CNS) relapse of rhabdomyosarcoma (RMS) is unclear. We examined diagnosis, management, and outcomes of patients with RMS developing CNS relapse.

Methods: Records of 23 patients diagnosed with CNS relapse between 1999 and 2016 were reviewed. Median age at presentation of CNS relapse was 15 years (range, 1-34 years). High-risk features at initial presentation were as follows: 16 alveolar patients, 13 Stage IV, and 13 with primary tumor in parameningeal locations.

Results: CNS relapse occurred at a median 12 months (range, 1-23 months) from diagnosis and most common presenting symptoms were headache (n = 9), nausea/vomiting (n = 8), visual difficulty (n = 5), and none (n = 5). Leptomeningeal metastases were detected in 21 patients while only 2 developed parenchymal metastases without leptomeningeal involvement. Fifteen patients received CNS-directed radiation therapy (RT), including craniospinal irradiation to a median 36 Gy (range, 18-36 Gy) and/or whole brain radiotherapy to a median 30 Gy (range, 6-41.4 Gy). Three patients received concurrent chemotherapy. Follow-up magnetic resonance imaging was conducted in 13 patients after RT initiation with 8 demonstrating improvement, 2 with stable disease, and 3 with progression. Twelve patients were tested for reactivity to I-131-labeled monoclonal antibody 8H9, and three tested positive and received at least one intra-Ommaya dose; all three lived >12 months post-CNS relapse. Twenty‐two patients died of CNS disease and one of treatment complications, with metastatic disease at other sites. Median survival post-CNS relapse was 5 months (range, 0.1-49 months).

Conclusions: The prognosis for patients with RMS developing CNS relapse remains poor. Treatment including CNS-directed RT should be considered and investigation into preventative therapies is warranted.

Keywords: CNS relapse; immunotherapy; radiation therapy; rhabdomyosarcoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1:
Figure 1:
Kaplan-Meier curves for all patients included in study. Median survival post-CNS relapse was 5 months (range, 0.1–49 months).
Figure 2:
Figure 2:
Survival post-CNS relapse in patients receiving CNS-directed RT versus those not receiving CNS-directed RT.
See this image and copyright information in PMC

Comment in

References

    1. Gerson JM, Jaffe N, Donaldson MH Tefft M. Meningeal seeding from rhabdomyosarcoma of the head and neck with base of the skull invasion: recognition of the clinical evolution and suggestions for management. Med Pediatr Oncol 1978;5:137–144. - PubMed
    1. Salunke P, Sura S, Gupta K, Tripathi M Aggarwal A. Middle ear rhabdomyosarcoma infiltrating the petrous with diffuse leptomeningeal spread in a child. J Pediatr Neurosci 2012;7:103–105. - PMC - PubMed
    1. Yang JC, Wexler LH, Meyers PA Wolden SL. Parameningeal rhabdomyosarcoma: outcomes and opportunities. Int J Radiat Oncol Biol Phys 2013;85:e61–66. - PubMed
    1. Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978–1997. Med Pediatr Oncol 2002;38:22–32. - PubMed
    1. Kline RM, Oseas RS, Jolley SG, et al. Leptomeningeal metastasis from a paraspinal rhabdomyosarcoma with a der(13)t(1;13)(q23;q32) in a 14-month-old boy. Cancer Genet Cytogenet 1997;98:97–101. - PubMed

MeSH terms

LinkOut - more resources